This Month
Hospitals says insurance premium hikes will not fix funding crisis
Private hospital operators also call for changes to the way in which the funding insurers contribute to the healthcare system is calculated.
- Michael Smith
Health insurers ask for big premium rise in new headache for Labor
Major funds have kicked off negotiations with the Health Department, and concede the rise they want creates a “very difficult situation” for Anthony Albanese.
- Michael Smith
- Exclusive
- Healthcare
Big pharma takes on doctors over homebrew cancer treatments
Australia’s top nuclear physicians say their patients will die earlier and in more pain if they are forced to stop making more affordable alternatives.
- Michael Smith
Two bidders through to I-MED next phase; final bids due November 29
Street Talk understands Bain Capital and Macquarie Asset Management and jostling for the $4 billion radiology giant.
- Sarah Thompson, Kanika Sood and Emma Rapaport
Plastic surgeons say the ‘ballet body’ is in. Here’s what that means.
Fuelled by the rise of the blockbuster drugs Ozempic and Wegovy, thinness is making a comeback.
- Frances Vinall
Navis Capital prepares $1b-plus exit at Device Technologies
Latham is expected to use a successful exit of Device - which would also mark Navis Capital’s largest deal ever in Australia – to underpin the billion-dollar raise for his ninth fund in 2025.
- Sarah Thompson, Kanika Sood and Emma Rapaport
Animal spirits: sponsors, trade stalk Apiam Animal Health
Sources said Vizard has fielded a handful of non-binding, indicative proposals this year, including from EQT, Quadrant and a trade player out of Canada.
- Sarah Thompson, Kanika Sood and Emma Rapaport
Indicative offers land for TPG’s golden child, the $4b CRO Novotech
At least three credible players have come forward with first-round offers for Novotech, but that doesn’t mean the business has succeeded in seducing every dealmaker in town.
- Sarah Thompson, Kanika Sood and Emma Rapaport
The start-up revolutionising male fertility tests
A home testing kit for men helps avoid the inconvenience and embarrassment of trips to IVF clinics.
- Michael Smith
Weight loss wars: a century on, the battle heats up
America’s Eli Lilly is locked in a fight with Denmark’s Novo Nordisk to control the weight loss market. One product could hold the key.
- Oliver Barnes
- Exclusive
- Healthcare
Wesfarmers says health division booming as Australians get sicker
The boss of Wesfarmer’s Health division says demand for digital services is increasing.
- Michael Smith
Fund private hospitals or risk patient safety: surgeons
Surgeons and other medical specialists say the government must help bail out private hospitals and reform the way insurers fund the system.
- Michael Smith
Saving Amy: how a DNA test identified cancer risk
Like other women in her family, Amy Soulsby was diagnosed with an aggressive form of breast cancer. Her only regret is that she didn’t do the genome test earlier.
- Michael Smith
The plan to save Australian lives with nationwide DNA screening
An ambitious vision to introduce mass genetic testing to the entire Australian adult population is being hailed as a solution to the country’s healthcare crisis. But can the health system cope?
- Michael Smith
- Opinion
- Health insurance
Health insurers have landed in a world of pain, political or otherwise
They’re under fire from parliamentarians and hospitals for making too much profit, and yet are caught in a customer land grab that is shaving away profits.
- Michael Smith
Like it or not, you’re already being cloned
We’re not all as photogenic as Demi Moore, but genetic data-doubles are becoming par for the course.
- Simon Ings
Navis Capital’s Device Tech stocks up M&A war chest
Street Talk understands Device Tech’s lenders have blessed the pan-Asian buyout firm’s decision to raise $150 million in fresh debt to fund M&A.
- Sarah Thompson, Kanika Sood and Emma Rapaport
- Updated
- Healthcare
Sigma shares surge as it offers concessions for Chemist Warehouse deal
The pharmacy retailer and wholesaler says its franchisees will be allowed to leave without being penalised if it secures the $8.8 billion merger.
- Updated
- Michael Smith
ResMed projects high single-digit revenue growth until 2030
The sleep devices giant expects revenue to grow in the high single-digits for the next five years as it deflects the Ozempic effect.
- Michael Smith
September
Pacific Smiles board set to reject Genesis’ $300m bid
Street Talk understands the dental chain’s board will reject Genesis’ $1.90 per share bid later today.
- Sarah Thompson, Kanika Sood, e and Emma Rapaport
